A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

• Status: Completed
• Trial end date: 2019-05-30

Summary

The purpose of the study is to evaluate the effect of stable coadministered oxcarbazepine (OXC), on the pharmacokinetics (PK), safety, tolerability of padsevonil (PSL) and the plasma PK of PSL metabolites, UCB1431322-000 and UCB1447499-000, in study participants with epilepsy compared with study participants co-medicated with stable doses of levetiracetam (LEV), lamotrigine (LTG) or brivaracetam (BRV) therapy.

• Phase: Phase 1

Details

• Lead Sponsor: UCB Biopharma S.P.R.L.
• Treatments: Anticonvulsants; Brivaracetam; Carbamazepine; Etiracetam; Lamotrigine; Levetiracetam; Oxcarbazepine; Piracetam